We are live on ! Find out more

Aurinia Pharmaceuticals

AUPH

Market cap $2.3B

17.29 USD

+0.04

0.23%

At close Updated Oct 28, 11:10 AM EDT

1 day

0.23%

5 days

1.71%

1 month

4.66%

3 months

15.57%

6 months

7.79%

Year to date

12.64%

1 year

36.9%

5 years

-42.29%

10 years

435.29%

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 128

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 55.6%

Neutral 33.3%

Negative 11.1%

Zacks Investment Research

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline

Zacks Investment Research

Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term

Zacks Investment Research

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Zacks Investment Research

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS Growth

Healthcare stocks have outperformed in the past month amid a rotation away from the AI trade and other risk-on investments. Global fund managers increased positions in healthcare more than any other sector or asset, according to Bank of America's July survey. In volatile markets, investors tend to pivot to defensive sectors, and healthcare has been a top performer during periods of uncertainty, including ahead of November's U.S. midterm elections.

Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS Growth

See News Rankings

Price charts implemented using Lightweight Charts™